Held by 2 specialist biotech funds
**Signal Note: Eventide/PWR Initiation** Eventide's $37.6M entry into Quanta Services (a power infrastructure/renewable energy contractor) appears misaligned with typical biotech thesis—PWR operates in grid modernization and energy transition, not therapeutics. This suggests either a portfolio diversification move into values-aligned infrastructure plays or a data error in the filing; clarification needed on strategic rationale given Eventide's biotech-focused mandate.